Agilent, Florida International Developing Screening Methods for Designer Drugs | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies today announced a collaboration with Florida International University to develop methods for the identification and characterization of designer drugs.

Agilent is working with FIU's department of chemistry and biochemistry and its International Forensics Research Institute and is currently focused on developing and validating methods for rapid forensic screening and analysis to expand the capabilities of drug screening techniques using immunoassays, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.